Novartis Enterprise Value Trend from 2010 to 2020

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis Enterprise Value yearly trend continues to be relatively stable with very little volatility. Enterprise Value is likely to drop to about 236.3 B. During the period from 2010 to 2020, Novartis Enterprise Value destribution of quarterly values had r-value of  0.82 from its regression line and mean deviation of  30,014,820,898. Novartis Research and Development Expense is relatively stable at the moment as compared to the past year. Novartis reported last year Research and Development Expense of 9.4 Billion. As of 07/11/2020, Weighted Average Shares is likely to grow to about 2.6 B, while Gross Profit is likely to drop slightly above 32.6 B.

Search Historical Trends

Check Novartis financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Consolidated Income of 12.1 B, Cost of Revenue of 14.2 B or Earning Before Interest and Taxes EBIT of 14.8 B, as well as many exotic indicators such as Asset Turnover of 0.37, Book Value per Share of 29.65 or Current Ratio of 1.05. This can be a perfect complement to check Novartis Valuation or Volatility. It can also complement various Novartis Technical models. Additionally, see the analysis of Novartis Correlation with competitors.

Novartis Enterprise Value Marginal Breakdown

Showing smoothed Enterprise Value of Novartis AG with missing and latest data points interpolated. Enterprise Value (or EV) is usually referred to as Novartis theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Novartis AG debt, but would also pocket its cash. Enterprise Value is more accurate representation of Novartis value than its market capitalization because it takes into account all of Novartis AG existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.
ViewLast Reported 233.68 B10 Years Trend
Slightly volatile
 Enterprise Value 

Novartis Enterprise Value Regression Statistics

Arithmetic Mean 200,318,563,893
Geometric Mean 196,799,366,283
Coefficient Of Variation 18.49
Mean Deviation 30,014,820,898
Median 213,765,803,152
Standard Deviation 37,046,198,581
Range 109,119,882,422
R-Value 0.82
R-Squared 0.68
Significance 0.001798
Slope 9,208,453,962

Novartis Enterprise Value Over Time

2010128.6 B
2011148.6 B
2012168.9 B
2013208.7 B
2014236.1 B
2015213.8 B
2016190.2 B
2017216.1 B
2018218.5 B
2019237.7 B
2020236.3 B

Other Fundumenentals of Novartis AG

About Novartis Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Enterprise Value, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B

Did you try this?

Run Positions Ratings Now


Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Novartis Correlation with competitors. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page